New UGent / VUB spin-off Gulliver Biomed brings llama antibodies to the broad research community

(15-10-2018) Gulliver Biomed aims to develop nanobodies for researchers in knowledge institutions and companies.

Gulliver Biomed will develop customer-oriented antibodies in lamas that can then be used as a tool in fundamental research, but also for evaluation in (pre-) clinical studies as potential candidates for diagnostic or therapeutic applications. These unique antibodies, also known as nanobodies, were discovered at the VUB in the late 1980s.

Antibodies in general are known as workhorses in biomedical research and are widely used in many laboratories worldwide. In recent years it became clear that many experiments with 'classic' antibodies are difficult to reproduce. This makes the translation of research results to the clinical environment particularly difficult and even risky. Nanobodies can be cloned, minimizing variations in research results. In addition, nanobodies offer a number of new applications that are almost impossible to achieve with 'classic' antibodies.

Gulliver Biomed aims to develop nanobodies for researchers in knowledge institutions and companies in their scientific search for new treatment methods for cancer, cardiovascular diseases, infectious diseases or amyloid disorders such as Alzheimer's disease. The company will also expand its own portfolio and implement new applications for nanobodies.

The technological expertise is based on the research work in the group of prof. Dr. Jan Gettemans (Nanobody Lab, Department of Biochemistry, Faculty of Medicine and Health Sciences).